Redefining the clinical management of type 2 diabetes: Matching therapy to pathophysiology

European Journal of Clinical Investigation

Volumn 32, Issue SUPPL. 3, 2002, Pages 46-53

  Gerich, John E ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

cell dysfunction; Insulin resistance; Pathogenesis; Thiazolidinediones

Indexed keywords

B LYMPHOCYTE; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; DIET; DISEASE COURSE; GLUCOSE BLOOD LEVEL; METABOLISM; PANCREAS ISLET; PHYSIOLOGY; STATISTICS;

INSULIN;

BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIET; DISEASE PROGRESSION; HUMANS; INSULIN; INSULIN RESISTANCE; ISLETS OF LANGERHANS; STATISTICS;

EID: 18744408481     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1046/j.1365-2362.32.s3.6.x     Document Type: Review

References (75)

1. Gerich JE. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev 1998;19:491-503.
2. Hamman RF. Genetic and environmental determinants of non-insulin- dependent diabetes mellitus (NIDDM). Diabetes Metab Rev 1992;8:287-338.
3. American Diabetes Association. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183-96.
4. Ferrannini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998;19:477-90.
5. Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. J Am Med Assoc 1999;281:2005-12.
6. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15:297-303.
7. Granner DK, O'Brien RM. Molecular physiology and genetics of NIDDM. Importance of metabolic staging. Diabetes Care 1992;15:369-95.
8. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992;15:318-68.
9. Cavaghan MK, Ehrmann DA, Polonsky KS. Interactions between insulin resistance and insulin secretion in the development of glucose intolerance. J Clin Invest 2000;106:329-33.
10. Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS. Treatment with the oral antidiabetic agent troglitazone improves β cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 1997;100:530-7.
11. Osei K, Gaillard T, Schuster DP. Pathogenetic mechanisms of impaired glucose tolerance and type II diabetes in African-Americans. The significance of insulin secretion, insulin sensitivity, and glucose effectiveness. Diabetes Care 1997;20:396-404.
12. Tripathy D, Carlsson M, Almgren P, Isomaa B, Taskinen MR, Tuomi T et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance: lessons from the Botnia Study. Diabetes 2000;49:975-80.
13. Gerich JE. Metabolic abnormalities in impaired glucose tolerance. Metabolism 1997;46:40-3.
14. DeFronzo RA, Bonadonna RC, Ferrannini E, Alberti KG, Zimmet P, DeFronzo RA. editors. Pathogenesis of NIDDM. In: International Textbook of Diabetes Mellitus. New York: Wiley and Sons;1997, pp. 635-712.
15. DeFronzo RA. Lilly lecture 1987. The triumvirate: β-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988;37:667-87.
16. Pimenta W, Korytkowski M, Mitrakou A, Jenssen T, Yki-Jarvinen H, Evron W et al. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. J Am Med Assoc 1995;273:1855-61.
17. Gerich JE. Pathogenesis and treatment of type 2 (noninsulin-dependent) diabetes mellitus (NIDDM). Horm Metab Res 1996;28:404-12.
18. Cerasi E. Insulin deficiency and insulin resistance in the pathogenesis of NIDDM. Is a divorce possible? Diabetologia 1995;38:992-7.
19. Cerasi E, Luft R. Insulin response to glucose infusion in diabetic and non-diabetic monozygotic twin pairs. Genetic control of insulin response? Acta Endocrinol (Copenh) 1967;55:330-45.
20. Pyke DA, Taylor KW. Glucose tolerance and serum insulin in unaffected identical twins of diabetics. Br Med J 1967;4:21-2.
21. Barnett AH, Spiliopoulos AJ, Pyke DA, Stubbs WA, Burrin J, Alberti KG. Metabolic studies in unaffected co-twins of non-insulin-dependent diabetics. Br Med J (Clin Res Ed) 1981;282:1656-8.
22. Vaag A, Henriksen JE, Madsbad S, Holm N, Beck-Nielsen H. Insulin secretion, insulin action, and hepatic glucose production in identical twins discordant for non-insulin-dependent diabetes mellitus. J Clin Invest 1995;95:690-8.
23. Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998;47:1643-9.
24. Scheen AJ. From obesity to diabetes: why, when and who? Acta Clin Belg 2000;55:9-15.
25. Elbein SC, Wegner K, Kahn SE. Reduced β-cell compensation to the insulin resistance associated with obesity in members of Caucasian familial type 2 diabetic kindreds. Diabetes Care 2000;23:221-7.
26. American Diabetes Association. The pharmacological treatment of hyperglycemia in NIDDM. Diabetes Care 1995;18:1510-18.
27. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
28. UK Prospective Diabetes Study (UKPDS) Group. UK prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes 1995;44:1249-58.
29. Levy J, Atkinson AB, Bell PM, McCance DR, Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. Diabet Med 1998;15:290-6.
30. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A et al. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998;47:1326-34.
31. Higa M, Zhou YT, Ravazzola M, Baetens D, Orci L, Unger RH. Troglitazone prevents mitochondrial alterations, β cell destruction, and diabetes in obese prediabetic rats. Proc Natl Acad Sci USA 1999;96:11513-18.
32. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol 1999;84:11J-14J.
33. Bak JF, Moller N, Schmitz O, Saaek A, Pedersen O. In vivo insulin action and muscle glycogen synthase activity in type 2 (non-insulin-dependent) diabetes mellitus: effects of diet treatment. Diabetologia 1992;35:777-84.
34. Freidenberg GR, Reichart D, Olefsky JM, Henry RR. Reversibility of defective adipocyte insulin receptor kinase activity in non-insulin-dependent diabetes mellitus. Effect of weight loss. J Clin Invest 1988;82:1398-406.
35. Beck-Nielsen H, Pedersen O, Sorensen NS. Effects of dietary changes on cellular insulin binding and in vivo insulin sensitivity. Metabolism 1980;29:482-7.
36. Beck-Nielsen H, Pedersen O, Lindskov HO. Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese diabetics for one year. Acta Endocrinol (Copenh) 1979;90:103-12.
37. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT Diabetes Study. Diabetes Care 1997;20:537-44.
38. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001;344:1343-50.
39. Mann JI. Can dietary intervention produce long-term reduction in insulin resistance? Br J Nutr 2000;83 (Suppl. 1):S169-S172.
40. Gerstein HC. Glucose: a continuous risk factor for cardiovascular disease. Diabet Med 1997;14:S25-S31.
41. Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk). Br Med J 2001;322:15-18.
42. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996;45:1661-9.
43. Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001;134:61-71.
44. Mimura K, Umeda F, Hiramatsu S, Taniguchi S, Ono Y, Nakashima N et al. Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes. Diabet Med 1994;11:685-91.
45. 2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression. Diabetes 2000;49:346-55.
46. Dobashi K, Asayama K, Nakane T, Kodera K, Hayashibe H, Nakazawa S. Troglitazone inhibits the expression of inducible nitric oxide synthase in adipocytes in vitro and in vivo study in 3T3-L1 cells and Otsuka Long-Evans Tokushima Fatty rats. Life Sci 2000;67:2093-101.
47. Oakes ND, Kennedy CJ, Jenkins AB, Laybutt DR, Chisholm DJ, Kraegen EW. A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat. Diabetes 1994;43:1203-10.
48. Sreenan S, Keck S, Fuller T, Cockburn B, Burant CF. Effects of troglitazone on substrate storage and utilization in insulin-resistant rats. Am J Physiol 1999;276:E1119-E1129.
49. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and β-cell dysfunction. Eur J Clin Invest 2002;32 (Suppl. 3):14-23.
50. Greenberg AS, McDaniel ML. Identifying the links between insulin resistance and β-cell function: the role of cytokines;. Eur J Clin Invest 2002;32 (Suppl. 3):24-34.
51. Patel J, Miller E, Patwardhan R. Rosiglitazone (BRL49653) monotherapy has significant glucose lowering effect in type 2 diabetic patients. Diabetes 1998;47 (Suppl. 1):A17.
52. Carey DG, Cowin GJ, Galloway GJ, Dodrell D, Matfin G. Rosiglitazone improves insulin sensitivity and decreases hepatic fat in patients with type 2 diabetes. 11 th International Congress of Endocrinology. Sydney, Australia. 29th October - 2nd November, Poster P0645A, 2000.
53. McGarry JD, Dobbins RL. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 1999;42:128-38.
54. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. Diabetes 1995;44:863-70.
55. Rossetti L, Giaccari A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990;13:610-30.
56. Shimabukuro M, Zhou YT, Lee Y, Unger RH. Troglitazone lowers islet fat and restores beta cell function of Zucker diabetic fatty rats. J Biol Chem 1998;273:3547-50.
57. Dubois M, Pattou F, Kerr-Conte J, Gmyr V, Vandewalle B, Desreumaux P et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000;43:1165-9.
58. Suter SL, Nolan JJ, Wallace P, Gumbiner B, Olefsky JM. Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 1992;15:193-203.
59. Berkowitz K, Peters R, Kjos SL, Goico J, Marroquin A, Dunn ME et al. Effect of troglitazone on insulin sensitivity and pancreatic β-cell function in women at high risk for NIDDM. Diabetes 1996;45:1572-9.
60. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky JM. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93.
61. Wolffenbuttel BH, Gomis R, Squatrito S, Jones NP, Patwardhan RN. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. Diabet Med 2000;17:40-7.
62. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. J Am Med Assoc 2000;283:1695-702.
63. Jones NP, Mather R, Owen S, Porter LE, Patwardhan R. Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin. Diabetologia 2000;43:A192.
64. Salzman A, Patel J. Rosiglitazone therapy is not associated with hepatotoxicity. Diabetes 1999;48 (Suppl. 1):A95.
65. Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Ther 2000;22:1395-409.
66. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614-19.
67. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:854-65.
68. Groop LC. Insulin resistance: The fundamental trigger of type 2 diabetes. Diabetes Obes Metab 1999;1 (Suppl. 1):S1-S7.
69. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 2000;247:301-10.
70. Daubresse JC, Kolanowski J, Krzentowski G, Kutnowski M, Scheen A, van Gaal L. Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. Obes Res 1996;4:391-6.
71. Girard J. Is leptin the link between obesity and insulin resistance? Diabetes Metab 1997;23:16-24.
72. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
73. Jewett DC, Cleary J, Levine AS, Schaal DW, Thompson T. Effects of neuropeptide Y on food-reinforced behavior in satiated rats. Pharmacol Biochem Behav 1992;42:207-12.
74. Nauck MA, Holst JJ, Willms B, Schmiegel W. Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes 1997;105:187-95.
75. Gutniak MK, Larsson H, Sanders SW, Juneskans O, Holst JJ, Ahrén B. GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions. Diabetes Care 1997;20:1874-9.